Tandem Diabetes Care reported Q4 FY2025 worldwide sales of USD 290.4 million (+3% GAAP; +15% non-GAAP), with US sales of USD 210.5 million (-2% GAAP; +14% non-GAAP) and international sales of USD 79.9 million (+17%). Q4 gross margin was 58% (GAAP), operating income was USD 8.3 million, and net loss was USD 0.6 million; adjusted EBITDA was USD 32.9 million (11% margin). Q4 worldwide pump shipments were 38,000 (27,000 in the US). For FY2025, Tandem Diabetes Care posted worldwide sales of USD 1.01 billion (+8% GAAP; +12% non-GAAP), including USD 706.9 million in the US (+5% GAAP; +10% non-GAAP) and USD 307.8 million internationally (+15%). FY2025 gross margin was 54% (GAAP), operating loss was USD 187.3 million, and net loss was USD 204.7 million; adjusted EBITDA was negative USD 46.1 million. FY2025 pump shipments exceeded 126,000. Recent updates included the start of a global rollout of t:slim X2 integration with Abbott’s FreeStyle Libre 3 Plus sensor, the launch of Android mobile control for the Tandem Mobi system, the introduction of a pay-as-you-go pharmacy structure in the US, the start of direct commercial operations in select European countries, and the filing of a 510(k) with the FDA for a pregnancy indication for Control-IQ+. For FY2026, Tandem Diabetes Care guided to sales of approximately USD 1.07 billion to USD 1.09 billion, gross margin of approximately 56% to 57%, adjusted EBITDA margin of approximately 5% to 6%, and pump shipment growth of approximately 10% to 11%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tandem Diabetes Care Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260219656063) on February 19, 2026, and is solely responsible for the information contained therein.